Expansion Therapeutics has a portfolio with genetic disorders in it that it has been raising financing to fight. Myotonic dystropy type 1 (DM1) is included and is the leading cause of adults developing muscular dystrophy, there has been over $55 million added to cover fighting DM1. Several corporations including 5AM Ventures, RA Capital Management, and Sanofi Ventures took part in the financing for DM1.
DNA transfers molecules of RNAa which get converted into proteins, DM1 reaching toxic levels in the cells is what cause DM1 to occur. This causes the muscles, hormonal system, respiratory system, heart and central nervous system be start becoming defective. DM1 can affect whole families and it gets worse with each generation.
There is not currently an effective way to treat DM1, Expansion Therapeutics is creating medication to confront the RNA driven illnesses. Hereditary illnesses that do not respond to current medical interventions adequately known as expansion repeat disorders are the focus of medications and research from Expansion Therapeutics. Matthew D. Disney Ph.D’s research was used as the basis to the approach.
Scott M. Rocklage, Ph.D, 5AM Ventures managing partner has issued a press release which stated the team’s main researcher is Mr. Disney. The last twelve years of research and work the team has completed are gratifying for him, and small molecule medications can be addressed with RNA related diseases. The team is close to creating treatments that will help those with direst medical needs.
Expansion Therapeutics and Dr. Rocklage have plans to advance the targeting of RNA with small molecule medicines. They are eager to continue creating medications for those who do not have options. Learn more: https://ideamensch.com/scott-rocklage/
Scott Rocklage is the co-founding partner at 5am Ventures. He since joined the company back in 2003 and quickly became the managing partner in 2004. This company is the leading venture firm in developing next generation life-science. They support other companies in building ground-breaking medicine and researching health sciences. They range from preventing numerous illnesses, to even diagnoses. 5am Venture consists of a team full of investors that are all experts in:
• strong scientific and medical research
• legal operations
Scott Rocklage has had over 20 years of healthcare management and leadership experience. He is also responsible for three U.S New Drug Applications getting approved by the FDA and six other drugs being entered into clinical trials. In his early life, Rocklage went to study at the University of California and graduated with a Bachelor of Science degree in Chemistry. After that, he decided to pursue his Ph.D in Chemistry and obtained it from the Massachusetts Institute of Technology. Learn more: https://www.dialdish.com/scott-rocklage-seeks-to-conquer-cancer-by-targeting-mutant-rna-molecules/
Dr. Rocklage is now partnering with Expansion Therapeutics in finding a cure for different diseases concerning RNA-triggered illnesses. Now, these different diseases can be treated with medications and Expansion Therapeutics won’t rest until they’ve figured one out. Dr. Scott Rocklage is also by their side each step of the way trying to figure out other options for patients.
Myotonic Dystrophy Type I, or in other words, DM1 has been the leading cause of muscular dystrophy in adults. This mainly happens when RNA levels reach a toxic proportion in the human body. It can be very life-therenting for anyone as many of the body’s systems begin to shut down including the:
• Respiratory system
• Central nervous system
• Heart and Muscles
• Gastrointestinal system
• Hormonal system
Since many of these RNA illnesses are hereditary, Expansion Therapeutics knew something had to be done.
As a result of this, the company decided to add over $55 million dollars to cover expenses in order to find a cure! With this new budget, Rocklage and his team is there to help with all the leading and financing!